Skip to main content
. 2023 Feb 13;15(2):631. doi: 10.3390/pharmaceutics15020631

Figure 6.

Figure 6

Biosafety of the formulations. (A) Cytotoxicity of blank PCLP against HUVECs at the indicated concentrations for 48 h (n = 6). (B) Cytotoxicity of blank PCLP against HepG2 cells at the indicated concentrations for 48 h (n = 6). (C) Body weight of mice after various treatments (n = 5). (D) H & E-stained slices of the major organs after treatment. Biochemical analysis of (E) ALT and AST, (F) LDH and CK, (G) UREA and CREA in HepG2 tumor-bearing BALB/c nude mice treated with different formulations (n = 4). ALT: alanine aminotransferase; AST: aspartate aminotransferase; CK: creatine kinase; CREA: creatinine; LDH: lactate dehydrogenase; UREA: urea.